Gain detailed insights into the trading activity of Congress members for Arrowhead Pharma on our government trades page. Stay updated on how elected officials are investing in ARWR.

Arrowhead Pharma - Government Trades

Arrowhead Pharma

Arrowhead Pharmaceuticals Inc is an American biotechnology company. Its main target is the development of medicine to treat diseases with a genetic origin, characterized by the overproduction of one or more proteins. Its medical solutions are aimed at the genes that trigger the diseases. Its portfolio includes drugs targeting hepatitis B, Alpha-1 Antitrypsin Deficiency, thrombosis and angioedema, clear-cell and renal cell carcinoma, and cardiovascular disease.

The Archer Aviation Trade

Mid Cap

News

Movers

Trading Ideas

ACHR

ARWR

BHVN

Hims & Hers Health, Inc. Class A Common Stock

HIMS

IREN

JOBY

SOUN

SRPT

SRRK

URBN

8 mid-cap stocks saw impressive gains last week. Archer, Scholar Rock, Arrowhead, Iris Energy, Hims &amp; Hers, SoundHound, Joby Aviation, and Urban Outfitters all performed well.

Archer Aviation, Hims &amp; Hers Health And Urban Outfitters Are Among Top 8 Mid-Cap Gainers Last Week (Nov 25-Nov 29): Are The Others In Your Portfolio?

rivian shutter2

Large Cap

CPRT

ESTC

EXAS

MRNA

RIVN

RKLB

SNAP

ULTA

Top performers last week: RIVN, RKLB, SRPT, EXAS, ESTC, ULTA, MRNA, RL, CPRT, SNAP. Any in your portfolio? Citigroup raises price target on ULTA and SNAP.

Rivian Automotive, Rocket Lab And Moderna Are Among Top 10 Large-Cap Gainers Last Week (Nov 25-Nov 29): Are The Others In Your Portfolio?

movers image

$BTC

AMBA

BTBT

FATE

MNSO

MRNO

U.S. stocks were lower, with the Dow Jones index falling more than 100 points on Wednesday.

Iris Energy, Arrowhead Pharmaceuticals, Urban Outfitters And Other Big Stocks Moving Higher On Wednesday

Modern,Pharmacy,With,Variety,Of,Medications,And,Cosmetics,For,Everyone

Arrowhead Pharmaceuticals Inc. (NASDAQ: ARWR) shares are trading higher Tuesday after the company announced a global licensing and collaboration agreement with Sarepta Therapeutics Inc. (NASDAQ: SRPT). Here&#39;s what you need to know.

Arrowhead Pharmaceuticals Shares Are On The Rise Today: What&#39;s Going On?

xr:d:DAFlBgQqXKI:2,j:3472667867116897537,t:23060606

Intraday Update

Markets

EMBC

HSAI

NGNE

POET

SGMO

SMRT

SMTC

J.M. Smucker Posts Upbeat Earnings, Joins LexinFintech, Semtech, Arrowhead Pharmaceuticals And Other Big Stocks Moving Higher On Tuesday

wall street ai16

Price Target

Analyst Ratings

FUBO

SPGI

TBLA

VALE

WULF

S&amp;P Global To Rally More Than 13%? Here Are 10 Top Analyst Forecasts For Friday

vaccine-4892059

Health Care

Arrowhead Pharmaceuticals shares are trading higher by more than 6% during Monday&#39;s session. The company announced that it presented preclinical data on ARO-INHBE.

Why Arrowhead Pharmaceuticals (ARWR) Stock Is Seeing Blue Skies

biotech shutter

Biotech

Equities

Previews

DSKYF

NTLA

REGN

VRNA

XFOR

Biotech investing is risk-fraught but the returns could be staggering if one chooses to take the educated approach. 

5 Biotech Stocks With Key Catalysts This Week: Merck, Intellia, Verona, And More

General

Arrowhead Pharmaceuticals announced Phase 3 PALISADE study results showing significant triglyceride reduction in familial chylomicronemia syndrome patients treated with plozasiran.

Why Is Arrowhead Pharmaceuticals Stock Trading Higher On Monday?

ADSK

AGIO

CGON

COHR

DNLI

GERN

GPCR

LQDA

NVAX

OLMA

PARA

SKYW

SMMT

SRCL

TWST

VERA

Stericycle, MarineMax, Agios Pharmaceuticals And Other Big Stocks Moving Higher On Monday

Arrowhead Pharmaceuticals, Inc. - Common Stock

Arrowhead Pharmaceuticals Inc

HC Wainwright &amp; Co. analyst Patrick Trucchio reiterates Arrowhead Pharma (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ARWR#NASDAQ">ARWR</a>) with a Buy and maintains $80 price target.

Reiteration

HC Wainwright & Co. Reiterates Buy on Arrowhead Pharma, Maintains $80 Price Target

S&amp;P 500 constituent Apollo Global Management is acquiring Barnes Group in a deal expected to be completed soon pending final conditions.&nbsp;

Arrowhead Pharmaceuticals To Replace  Barnes Group In S&P SmallCap 600, Effective Prior To Opening Of Trading On January 27

GWRE

Guidewire Software To Replace Arrowhead Pharmaceuticals In S&P MidCap 400, Effective Prior To Opening Of Trading On January 27

Arrowhead Pharmaceuticals Announces FDA Acceptance of New Drug Application For Plozasiran In Treatment Of Familial Chylomicronemia Syndrome

Chardan Capital analyst Keay Nakae maintains Arrowhead Pharma (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ARWR#NASDAQ">ARWR</a>) with a Buy and maintains $60 price target.

Chardan Capital Maintains Buy on Arrowhead Pharma, Maintains $60 Price Target

Arrowhead Pharmaceuticals Announced Interim Results From A Phase 1/2A Clinical Study Of ARO-CFB, The Company's Investigational RNA Interference (RNAi) Therapeutic Targeting Complement Factor B Being Developed As A Potential Treatment For Complement Mediated Diseases

HC Wainwright &amp; Co. analyst Patrick Trucchio maintains Arrowhead Pharma (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ARWR#NASDAQ">ARWR</a>) with a Buy and raises the price target from $60 to $80.

HC Wainwright & Co. Maintains Buy on Arrowhead Pharma, Raises Price Target to $80

<ul>
<li>In preclinical studies, investigational ARO-ALK7 silenced Activin receptor-like kinase 7 (ALK7) expression in adipose tissue, which led to reduced body weight and fat mass with preservation of lean muscle</li>
</ul>

Arrowhead Pharmaceuticals Has Filed A Request For Regulatory Clearance To Initiate A Phase 1/2a Trial Of ARO-ALK7 As A Potential Treatment For Obesity

These eight mid-cap stocks were the best performers in the last week. Are they in your portfolio?
<ol>
<li>Archer Aviation Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ACHR#NYSE">ACHR</a>) shares skyrocketed 65.57% last week.</li>
<li>Scholar Rock Holding Corporation (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SRRK#NASDAQ">SRRK</a>) stock jumped 49.61%  after rival Biohaven Ltd.'s (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BHVN#NYSE">BHVN</a>) taldefgrobep for spinal muscular <a href="https://www.benzinga.com//node/42169246" target="_blank" rel="noreferrer noopener">atrophy failed its Phase 3 study</a>.</li>
<li>Arrowhead Pharmaceuticals, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ARWR#NASDAQ">ARWR</a>) shares escalated 42.40% after it entered into a global licensing and collaboration agreement with Sarepta Therapeutics Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SRPT#NASDAQ">SRPT</a>) for multiple clinical <a href="https://www.benzinga.com//node/42196870" target="_blank" rel="noreferrer noopener">and preclinical siRNA programs</a>.</li>
<li>Iris Energy Limited (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/IREN#NASDAQ">IREN</a>) stock surged 38.99% after the company reported first-quarter results and several analysts raised <a href="https://www.benzinga.com//node/42214256" target="_blank" rel="noreferrer noopener">the price forecast on the stock</a>.</li>
<li>Hims &amp; Hers Health, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/HIMS#NYSE">HIMS</a>) shares upped 33.42% in response to President-elect Donald Trump's plans to nominate Marty Makary to lead the <a href="https://www.benzinga.com//node/42177219" target="_blank" rel="noreferrer noopener">Food and Drug Administration (FDA)</a>.</li>
<li>SoundHound AI, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SOUN#NASDAQ">SOUN</a>) stock grew 33.38%. The company recently announced the deployment of its conversational AI agent, Amelia, at <a href="https://www.benzinga.com//node/42145826" target="_blank" rel="noreferrer noopener">Apivia Courtage as part of the AEMA Group</a>.</li>
<li>Joby Aviation, Inc.'s (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/JOBY#NYSE">JOBY</a>) stock upped 31.62% after Toyota Motor Corp (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/TM#NYSE">TM</a>) <a href="https://www.benzinga.com//node/42169194" target="_blank" rel="noreferrer noopener">invested half a billion dollars</a> in it.</li>
<li>Urban Outfitters, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/URBN#NASDAQ">URBN</a>) shares increased 30.43% after the company reported third-quarter earnings and several analysts raised <a href="https://www.benzinga.com//node/42221225" target="_blank" rel="noreferrer noopener">the price forecast on the stock</a>.</li>
</ol>
Also Read:
<ul>
<li><a href="https://www.benzinga.com/news/large-cap/24/12/42256613/rivian-automotive-rocket-lab-and-moderna-are-among-top-10-large-cap-gainers-last-week-nov-25-nov-29-are-the-others-in-your-portfolio" target="_blank" rel="noreferrer noopener">Rivian Automotive, Rocket Lab And Moderna Are Among Top 10 Large-Cap Gainers Last Week (Nov 25-Nov 29): Are The Others In Your Portfolio?</a></li>
<li><a href="https://www.benzinga.com/news/large-cap/24/12/42256757/reddit-grab-and-autodesk-are-among-top-11-large-cap-losers-last-week-nov-25-nov-29-are-the-others-in-your-portfolio" target="_blank" rel="noreferrer noopener">Reddit, Grab And Autodesk Are Among Top 11 Large-Cap Losers Last Week (Nov 25-Nov 29): Are The Others In Your Portfolio?</a></li>
</ul>
Image via Archer

Archer Aviation, Hims & Hers Health And Urban Outfitters Are Among Top 8 Mid-Cap Gainers Last Week (Nov 25-Nov 29): Are The Others In Your Portfolio?

These ten large-cap stocks were the best performers in the last week. Are they in your portfolio?
<ol>
<li>Rivian Automotive, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RIVN#NASDAQ">RIVN</a>) shares jumped 22.06% after securing a<a href="https://www.benzinga.com//node/42184005" target="_blank" rel="noreferrer noopener"> $6.6 billion DOE loan commitment</a>.</li>
<li>Rocket Lab USA, Inc.&#8217;s (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RKLB#NASDAQ">RKLB</a>) stock surged 21.73% after it secured a $23.9 million CHIPS Act grant to enhance its <a href="https://www.benzinga.com//node/42216210" target="_blank" rel="noreferrer noopener">semiconductor operations in New Mexico</a>.</li>
<li>Sarepta Therapeutics, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SRPT#NASDAQ">SRPT</a>) stock upped 20.67% after the company announced a global licensing and collaboration agreement with Arrowhead Pharmaceuticals Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ARWR#NASDAQ">ARWR</a>) for <a href="https://www.benzinga.com//node/42196870" target="_blank" rel="noreferrer noopener">multiple clinical and preclinical siRNA programs</a>.</li>
<li>Exact Sciences Corporation (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/EXAS#NASDAQ">EXAS</a>) stock increased 16.98%. The Centers for Medicare &amp; Medicaid Services posted final payment determinations for its <a href="https://www.benzinga.com//node/42195803" target="_blank" rel="noreferrer noopener">2025 Clinical Laboratory Fee Schedule</a>.</li>
<li>Elastic N.V. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ESTC#NYSE">ESTC</a>) shares rose 16.29%. Wedbush Securities analyst Daniel Ives has significantly increased his optimism on the next phase of the AI revolution, focusing on its <a href="https://www.benzinga.com//node/42171519" target="_blank" rel="noreferrer noopener">transformative impact on the software sector</a>.</li>
<li>Ulta Beauty, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ULTA#NASDAQ">ULTA</a>) shares upped 14.13%. Citigroup analysts raised the<a href="https://www.benzinga.com/quote/ulta/analyst-ratings" target="_blank" rel="noreferrer noopener"> price forecast on the stock</a>.</li>
<li>Moderna (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MRNA#NASDAQ">MRNA</a>) <a href="https://www.benzinga.com//node/42197195" target="_blank" rel="noreferrer noopener">shares surged 12.58%</a> last week.</li>
<li>Ralph Lauren Corp (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/RL#NYSE">RL</a>) stock gained 11.72% last week.</li>
<li>Copart, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CPRT#NASDAQ">CPRT</a>) stock was up 11.41% after the company reported better-than-expected Q1 sales results.</li>
<li>Snap Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SNAP#NYSE">SNAP</a>) stock increased 12.18%. Citigroup analysts raised the <a href="https://www.benzinga.com/quote/snap/analyst-ratings" target="_blank" rel="noreferrer noopener">price forecast on the stock</a>.</li>
</ol>
Photo by rblfmr via Shutterstock

Bernstein analyst William Pickering maintains Arrowhead Pharma (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ARWR#NASDAQ">ARWR</a>) with a Market Perform and lowers the price target from $27 to $24.

Bernstein Maintains Market Perform on Arrowhead Pharma, Lowers Price Target to $24

U.S. stocks were lower, with the Dow Jones index falling more than 100 points on Wednesday.
Shares of Iris Energy Limited (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/IREN#NASDAQ">IREN</a>) rose sharply during Wednesday's session on the heels of the company's first-quarter financial results. Multiple analysts raised price <a href="https://www.benzinga.com/quote/IREN/earnings">targets following the print</a>.
After the market close on Tuesday, Iris reported first-quarter Bitcoin (CRYPTO: <a class="ticker" href="https://www.benzinga.com/quote/btc/usd">BTC</a>) mining revenue of $49.6 million. The company reported a 28% increase in AI Cloud Services revenue quarter-over-quarter to $3.2 million.
Iris Energy shares jumped 30.8% to $12.51 on Wednesday.
Here are some other big stocks recording gains in today's session.
<ul>
<li>Agora, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/API#NASDAQ">API</a>) gained 26.1% to $5.98.</li>
<li>Arrowhead Pharmaceuticals, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ARWR#NASDAQ">ARWR</a>) shares gained 20.9% to $25.45 following FY 2024 results.</li>
<li>Murano Global Investments Plc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MRNO#NASDAQ">MRNO</a>) jumped 18.4% to $11.13.</li>
<li>Kingsoft Cloud Holdings Limited (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/KC#NASDAQ">KC</a>) gained 17.1% to $6.99.</li>
<li>Urban Outfitters, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/URBN#NASDAQ">URBN</a>) shares surged 16% to $46.58 following third-quarter earnings. Citigroup upgraded the stock to Buy following the report.</li>
<li>Bit Digital, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BTBT#NASDAQ">BTBT</a>) gained 14.4% to $4.2802.</li>
<li>Fate Therapeutics, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/FATE#NASDAQ">FATE</a>) gained 14.4% to $3.0650.</li>
<li>Hut 8 Corp. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/HUT#NASDAQ">HUT</a>) shares jumped 12.8% to $27.56.</li>
<li>Archer Aviation Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ACHR#NYSE">ACHR</a>) gained 12.2% to $8.10.</li>
<li>MINISO Group Holding Limited (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MNSO#NASDAQ">MNSO</a>) climbed 7.2% to $18.66.</li>
<li>Bloom Energy Corporation (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BE#NYSE">BE</a>) shares gained 5.8% to $27.69.</li>
<li>Ambarella, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AMBA#NASDAQ">AMBA</a>) gained 5% to $71.82 after the company on Tuesday reported a year-over-year increase in third-quarter revenue results..</li>
</ul>
Now Read This: 
<ul>
<li><a href="https://www.benzinga.com/24/11/42213467/urban-outfitters-to-rally-around-47-here-are-10-top-analyst-forecasts-for-wednesday">Urban Outfitters To Rally Around 47%? Here Are 10 Top Analyst Forecasts For Wednesday</a></li>
</ul>

Piper Sandler analyst Edward Tenthoff maintains Arrowhead Pharma (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ARWR#NASDAQ">ARWR</a>) with a Overweight and lowers the price target from $62 to $45.

Piper Sandler Maintains Overweight on Arrowhead Pharma, Lowers Price Target to $45

Citigroup analyst Shawn Egan maintains Arrowhead Pharma (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ARWR#NASDAQ">ARWR</a>) with a Neutral and lowers the price target from $27 to $26.

Citigroup Maintains Neutral on Arrowhead Pharma, Lowers Price Target to $26

WIIM

Arrowhead Pharmaceuticals shares are trading higher. Chardan Capital maintained a Buy rating on the stock.

<h3>Gainers</h3>
<ul>
<li>Poseida Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PSTX#NASDAQ">PSTX</a>) shares moved upwards by 224.5% to $9.28 during Tuesday's pre-market session. The company's market cap stands at $904.4 million. </li>
<li>Caribou Biosciences (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CRBU#NASDAQ">CRBU</a>) stock rose 23.76% to $2.5. The company's market cap stands at $226.3 million. </li>
<li>Arrowhead Pharma (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ARWR#NASDAQ">ARWR</a>) shares increased by 21.07% to $22.75. The market value of their outstanding shares is at $2.8 billion. As per the press release, Q4 earnings came out today. </li>
<li>Neurogene (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NGNE#NASDAQ">NGNE</a>) stock rose 19.47% to $26.66. The market value of their outstanding shares is at $396.0 million. </li>
<li>Tactile Systems Tech (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TCMD#NASDAQ">TCMD</a>) stock increased by 18.12% to $22.35. The market value of their outstanding shares is at $536.3 million. </li>
<li>Embecta (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/EMBC#NASDAQ">EMBC</a>) stock increased by 18.04% to $17.01. The market value of their outstanding shares is at $981.5 million. As per the press release, Q4 earnings came out today. </li>
</ul>
<h3>Losers</h3>
<ul>
<li>Select Medical Hldgs (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SEM#NYSE">SEM</a>) shares declined by 43.8% to $21.75 during Tuesday's pre-market session. The company's market cap stands at $2.8 billion. </li>
<li>Alector (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ALEC#NASDAQ">ALEC</a>) stock declined by 34.35% to $2.6. The company's market cap stands at $254.6 million. </li>
<li>BrightSpring Health (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BTSGU#NASDAQ">BTSGU</a>) shares fell 20.77% to $55.01. </li>
<li>Scinai Immunotherapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SCNI#NASDAQ">SCNI</a>) shares decreased by 17.85% to $2.9. The market value of their outstanding shares is at $2.4 million. As per the news, the Q3 earnings report came out 2 days ago. </li>
<li>Cocrystal Pharma (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/COCP#NASDAQ">COCP</a>) stock declined by 10.14% to $1.95. The company's market cap stands at $19.8 million. </li>
<li>Amgen (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AMGN#NASDAQ">AMGN</a>) shares fell 9.94% to $264.78. The market value of their outstanding shares is at $142.3 billion. 
See Also: <a href="http://www.benzinga.com/money/best-healthcare-stocks/" title="www.benzinga.com/money/best-healthcare-stocks/">www.benzinga.com/money/best-healthcare-stocks/</a></li>
</ul>
This article was generated by Benzinga's automated content engine and reviewed by an editor.

ALEC

AMGN

BTSGU

COCP

CRBU

PSTX

SCNI

TCMD

12 Health Care Stocks Moving In Tuesday's Pre-Market Session

Arrowhead Pharma (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ARWR#NASDAQ">ARWR</a>) reported quarterly losses of $(5.00) per share which missed the analyst consensus estimate of $(4.45) by 12.36 percent. The company reported quarterly sales of $3.551 million which missed the analyst consensus estimate of $74.932 million by 95.26 percent.

Earnings

Earnings Misses

Arrowhead Pharma FY 2024 GAAP EPS $(5.00) Misses $(4.45) Estimate, Sales $3.551M Miss $74.932M Estimate

Arrowhead Pharmaceuticals Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ARWR#NASDAQ">ARWR</a>) shares are trading higher Tuesday after the company announced a global licensing and collaboration agreement with Sarepta Therapeutics Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SRPT#NASDAQ">SRPT</a>). Here&#8217;s <a href="https://www.benzinga.com/quote/ARWR/news">what you need to know.</a>
What To Know: The partnership grants Sarepta exclusive worldwide rights to Arrowhead's investigational RNA interference (RNAi) therapies for rare genetic diseases targeting muscle, the central nervous system (CNS) and the lungs.
The agreement focuses on Arrowhead's Targeted RNAi Molecule platform, which enables precise delivery of therapies designed to reduce the activity of disease-causing genes. 
Arrowhead will receive an upfront payment of $500 million, as well as a $325 million equity investment from Sarepta at a 35% premium. Additional terms include $250 million to be paid in $50 million installments over five years, up to $300 million in near-term milestone payments over the next year and potential tiered royalties on commercial sales.
Arrowhead CEO Christopher Anzalone called the agreement transformative, noting that the influx of capital extends the company's financial runway through 2028. This timeline positions Arrowhead to pursue the commercial launch of its first product, plozasiran, pending regulatory approval.
Sarepta sees the collaboration as a strategic expansion of its portfolio, complementing its expertise in gene therapy and Duchenne muscular dystrophy. Sarepta CEO Doug Ingram highlighted the potential for these RNAi programs to have a significant market impact. As part of the agreement, Ingram will join Arrowhead's Board of Directors.
Check This Out: <a href="https://www.benzinga.com/24/11/42195803/why-is-exact-sciences-stock-trading-higher-on-monday">Why Is Exact Sciences Stock Trading Higher On Monday?</a>
&#8220;The agreement affords multiple potential blockbuster opportunities, serves our strategic priorities for the remainder of the decade and beyond and diversifies our business model across one-time therapies and chronic treatments allowing for long-term growth and success,&#8221; Ingram said.
The collaboration is expected to close in early 2025, pending regulatory approval. Both companies have emphasized the agreement's significance in advancing treatments for rare genetic diseases, with additional details anticipated in their upcoming investor presentations.
ARWR Price Action: Arrowhead Pharmaceuticals shares were up 16.7% at $21.94 at the time of writing, according to <a href="https://pro.benzinga.com/dashboard">Benzinga Pro.</a>
<figure class="wp-block-image size-large is-resized"><a href="https://benzinga.slack.com/archives/D072651PB4K/p1727794380964569"><img loading="lazy" decoding="async" width="1024" height="540" src="https://editorial-assets.benzinga.com/wp-content/uploads/2024/11/26112407/ARWR-1024x540.png" alt="" class="wp-image-665810" style="width:497px;height:auto" srcset="https://editorial-assets.benzinga.com/wp-content/uploads/2024/11/26112407/ARWR-1024x540.png 1024w,https://editorial-assets.benzinga.com/wp-content/uploads/2024/11/26112407/ARWR-300x158.png 300w,https://editorial-assets.benzinga.com/wp-content/uploads/2024/11/26112407/ARWR-768x405.png 768w,https://editorial-assets.benzinga.com/wp-content/uploads/2024/11/26112407/ARWR.png 1140w" sizes="(max-width: 1024px) 100vw, 1024px" /></a></figure>
Read Next:
<ul>
<li><a href="https://www.benzinga.com/24/11/42194455/berry-global-sells-specialty-tapes-unit-for-540m-to-focus-on-consumer-growth">Merger-Bound Berry Global Agrees To Divest Specialty Tapes Unit For ~$540M</a></li>
</ul>
Image Via Shutterstock.

Arrowhead Pharmaceuticals Shares Are On The Rise Today: What's Going On?

Press Releases

Sarepta Therapeutics Announces Global Licensing and Collaboration Agreement with Arrowhead Pharmaceuticals for Multiple Clinical and Preclinical siRNA Programs

Arrowhead Pharmaceuticals Reports 2024 Fiscal Year-End Results

Arrowhead Pharmaceuticals to Participate in Upcoming December 2024 Conferences

Arrowhead Pharmaceuticals Requests Regulatory Clearance to Initiate Phase 1/2a Study of ARO-ALK7 for the Treatment of Obesity

Arrowhead Pharmaceuticals Presents Interim Clinical Data on ARO-CFB for the Treatment of Complement Mediated Diseases

Arrowhead Pharmaceuticals Reports Inducement Grants under NASDAQ Listing Rule 5635(c)(4)

Arrowhead Pharmaceuticals Initiates Phase 1/2a Study of ARO-INHBE for the Treatment of Obesity

Arrowhead Pharmaceuticals Announces Acceptance of New Drug Application by U.S. FDA of Plozasiran for the Treatment of Familial Chylomicronemia Syndrome

Arrowhead Pharmaceuticals to Webcast Fiscal 2025 First Quarter Results

Guidewire Software Set to Join S&P MidCap 400; Arrowhead Pharmaceuticals to Join S&P SmallCap 600

Government Trades

Arrowhead Pharmaceuticals Inc

top performing ARWR trades

Popular Channels

Tools & Features

Partners & Contributors

About Benzinga